Benzimidazole derivatives as therapeutic agents

Details Benzimidazole derivatives as therapeutic agents Benzimidazole derivatives as therapeutic agents

2006-08-08

2006-08-08

Stockton, Laura L. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S309700

Reexamination Certificate

active

07087632

ABSTRACT:
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

REFERENCES:
patent: 3255202 (1966-06-01), Johnson
patent: 3951968 (1976-04-01), Fauran et al.
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4356108 (1982-10-01), Schwab et al.
patent: 4873313 (1989-10-01), Crawford et al.
patent: 5202424 (1993-04-01), Vlassara et al.
patent: 5585344 (1996-12-01), Vlassara et al.
patent: 5688653 (1997-11-01), Ulrich et al.
patent: 5703092 (1997-12-01), Xue et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 5922770 (1999-07-01), Peschke et al.
patent: 5939526 (1999-08-01), Gaugler et al.
patent: 6100098 (2000-08-01), Newkirk
patent: 6316474 (2001-11-01), McCauley et al.
patent: 1476560 (1967-04-01), None
patent: 2160719 (1973-07-01), None
patent: 2 005 674 (1979-04-01), None
patent: WO 95/09838 (1995-04-01), None
patent: WO 95/35279 (1995-12-01), None
patent: WO 96/32385 (1996-10-01), None
patent: WO 97/22618 (1997-06-01), None
patent: WO 97/26913 (1997-07-01), None
patent: WO 97/39121 (1997-10-01), None
patent: WO 9739125 (1997-10-01), None
patent: WO 98/22138 (1998-05-01), None
patent: WO-98/27108 (1998-06-01), None
patent: WO 98/33492 (1998-08-01), None
patent: WO 99/07402 (1999-02-01), None
patent: WO 99/18987 (1999-04-01), None
patent: WO 99/25690 (1999-05-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 99/54485 (1999-10-01), None
patent: WO 00/20458 (2000-04-01), None
patent: WO 00/20621 (2000-04-01), None
patent: WO 01/12598 (2001-02-01), None
CA Registry No. 366489-63-6, Nov. 2, 2001.
CA Registry No. 366489-61-4, Nov. 2, 2001.
CA Registry No. 366489-58-9, Nov. 2, 2001.
CA Registry No. 366489-56-7, Nov. 2, 2001.
CA Registry No. 366489-47-6, Nov. 2, 2001.
CA Registry No. 366489-45-4, Nov. 2, 2001.
CA Registry No. 366489-42-1, Nov. 2, 2001.
CA Registry No. 366489-40-9, Nov. 2, 2001.
CA Registry No. 338410-76-7, May 25, 2001.
CA Registry No. 338410-71-2, May 25, 2001.
CA Registry No. 338410-59-6, May 25, 2001.
CA Registry No. 338410-56-3, May 25, 2001.
CA Registry No. 338410-55-2, May 25, 2001.
CA Registry No. 338410-51-8, May 25, 2001.
CA Registry No. 138369-72-9, Jan. 18, 1992.
CA Registry No. 138369-70-7, Jan. 18, 1992.
Mengelberg, CA 53:15063h, 1959.
Salgaonkar et al., Indian Drugs (2000), 37(11), pp. 547-550.
Balboni et al., CA 134 :66089, 2000.
Yatabe et al., CA 129 :95714, 1998.
Hoom et al., CA 127:336363, 1997.
Casella et al, CA 122:95181, 1995.
Varney et al., Journal of Medicinal Chemistry (1994), 37(15), pp. 2274-2284.
Nawwar et al., CA 119:250416, 1993.
Crane et al., CA 116:50261, 1992.
Cuadro et al., CA 109:128908, 1988.
Kamdar et al., CA 109:128903, 1988.
Aminabhavi et al., CA 107:23674, 1987.
Nandi et al., CA 106:138323, 1987.
Ohtani et al., CA 87:178868, 1977.
Maekawa et al., CA 85:154963, 1976.
Tiwari et al., CA 85:46510, 1976.
Maekawa et al., CA 85:21787, 1976.
Schubert et al., CA 81:120538, 1974.
Gualtieri et al., Journal of Medicinal Chemistry (1972), 15(4), pp. 420-422.
Schubert et al., CA 74:111961, 1971.
Kanaoka et al., CA 72:55332, 1970.
Aryuzina et al., CA 66:94952, 1967.
Golub et al., Science, vol. 286, Oct. 15, 1999, pp. 531-537.
PCT Notification of Transmittal of the International Search Report corresponding to PCT application from PCT/US02/06706 (“Benzimidazole Derivatives as Therapeutic Agents”), Jun. 26, 2002.
Albercio, F. & Carpino, L.A., “Coupling Reagents and Activation”Methods in Enzymology289:104-126, Academic Press, San Diego (1997).
Barton, J.W., “In Protection of N-H Bonds and NR3”Protective Groups in Organic Chemistry, J.F.W. McOmie, ED., Plenum Press, New York, NY (1973).
Berge, S.M., et al., “Pharmaceutical Salts”Journal of Pharmaceutical Sciences66:1-19 (1977).
Chitaley, K., et al., “Antagonism of Rho-Kinase Stimulates Rate Penile Erection via a Nitric Oxide-Independent Pathway”Nature Medicine7:119-122 (2002).
Degenhardt, T.P., et al., “Chemical Modification of Proteins by Methylglyoxal”Cell Mol. Biol., 44:1139-1145 (1998).
Dyer, D.G., et al., “Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging”J. Clin. Invest., 91:2463-2469 (1993).
Dyer, D.G., et al., “Formation of Pentosidine during Nonenzymatic Browning of Proteins by Glucose”J. Biol. Chem., 266:11654-11660 (1991).
Greene, T.W., “Protection for the Amino Group”Protective Groups in Organic Synthesis, John Wiley and Sons, New York, NY, Chapter 7 (1981).
Hammes, H.P., et al., “Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidation Product Nε-(Carboxymethyl) Lysine Independently of Glycohaemogobin Concentrations” Diabetologia, 42:603-607 (1999).
Hoffman, M.A., et al., “RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides”Cell, 97:889-901 (1999).
Hori, O., et al., “The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding site for Ampyhoterin”J. Biol. Chem., 270:25752-761 (1995).
Huttunen, H.J., et al., “Receptor for Advanced Glycation End Products (RAGE)-Mediated Neurite Outgrowth and Activation of NF-Kappa B Require the Cytoplasmic Domain of the Receptor But Different Downstream Signaling Pathways”J. Biol. Chem.274(28):19919-24 (1999).
Kumar, S.R., et al., “RAGE at th Blood-Brain Barrier Mediates Neurovascular Dysfunction Caus d by Amyloidβ1-40Peptide”Neurosci. Program, 141-#255.19 (2000).
Leder, A. et al., “v-HA-ras Transgene Abrogates the Initation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic Acid”Proc. Natl. Acad. Sci., USA, 87:9178-9182 (1990).
Li, J. et al., “Sp1-Binding elements in the Promoter of RAG Are Essential for Amphoterin-Mediated Gene Expression in Cultured Neuroblastoma Cells”J. Biol. Chem., 273:30870-30878 (1998).
Li, J. et al., “Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products,”J. Biol. Chem., 272:16498-16506 (1997).
Lugering, N. et al., “The Myeloic Related Protein MRP8/14 (27E10 Antigen)—Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function” Eur. J. Clin. Inves., 25:659-664 (1995).
Miyata, T. et al., “β2-Microglobulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis”J. Clin. Invest., 92:1243-1252 (1993).
Miyata, T. et al., “The Receptor for Advanced Glycation End Products (RAGE) Is a Central Mediator of the Interaction of AGE-β2Microglobulin with Human Mononuclear Phagocytes Via an Oxidant-Sensitive Pathway”J. Clin. Invest., 98:1088-1094 (1996).
Neeper, M., et al., “Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins”J. Biol. Chem., 267:14998-15004 (1992).
Parkkinen, J. et al., “Amphoterin, the 30-kDa Protein in a Family of HMG1-Type Polypeptides”J. Biol Chem., 268:19726-19738 (1993).
Rammes, A. et al., Myeloid-Related Protein (MRP) 8 and MRP 14, Calcium-Binding Proteins of the S100 Family, A

Affiliated with

Also associated with

Rating

Benzimidazole derivatives as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzimidazole derivatives as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole derivatives as therapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3640888